专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0119376A3 METHOD OF INHIBITING NF- kappa B WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS 审中-公开
标题翻译：抑制NF-κB与HEPARIN的方法，用于治疗心血管疾病和炎症
公开(公告)号：WO0119376A3
公开(公告)日：2001-12-13
申请号：PCT/US0024910
申请日：2000-09-12
申请人： CHARLOTTE MECKLENBURG HOSPITAL , KENNEDY THOMAS P
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/00 , A61P29/00 , A61K31/7024 , A61K31/70
CPC分类号： A61K31/727
摘要： Methods for treating heart failure and diabetic vascular disease in patients are provided. A therapeutically effective amount of heparin is administered to a patient to inhibit NF- kappa B activity in the patient, and thus treating or preventing heart failure or diabetic vascular disease.
摘要翻译：提供了治疗患者心力衰竭和糖尿病血管病的方法。对患者施用治疗有效量的肝素以抑制患者的NF-κB活性，从而治疗或预防心力衰竭或糖尿病性血管疾病。

2. 发明申请

WO0182918A8 METHOD FOR THE PREVENTION OF APOPTOSIS 审中-公开
标题翻译：防治疫苗的方法
公开(公告)号：WO0182918A8
公开(公告)日：2002-07-11
申请号：PCT/US0140639
申请日：2001-04-30
申请人： CHARLOTTE MECKLENBURG HOSPITAL , KENNEDY THOMAS P
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/04 , A61P9/10 , A61P43/00 , C08B37/10
CPC分类号： A61K31/727
摘要： et effet a été attribué à l'inhibition du complément, mais l'héparine présente également d'autres activités pouvant diminuer l'ischémie-reperfusion. Afin d'analyser ces mécanismes plus avant, nous avons comparé l'héparine et une héparine non anticoagulante O-désulfatée à activité anti-complément largement réduite. Administrée lors de la reperfusion de l'artère coronaire dans un modèle canin d'infarctus du myocarde, à la fois l'héparine et l'héparine O-désulfatée réduisent de manière égale l'adhérence de neutrophiles à l'endothélium de l'artère coronaire ischémiée et reperfusée, l'afflux de neutrophiles dans le myocarde ischémié et reperfusé, la nécrose myocardique et la libération de créatine kinase dans le plasma. L'héparine et l'héparine O-désulfatée empêchent également un dysfonctionnement de la relaxation coronaire dépendant de l'endothélium à la suite d'une lésion ischémique. En outre, l'héparine et l'héparine O-désulfatée inhibent la translocation du factllules endothéliales humaines et réduisent la liaison ADN NF-λB dans l'endothélium humain et le myocarde de rat ischémié et reperfusé. Ainsi, l'héparine et l'héparine non anticoagulante diminuent la lésion d'ischémie-reperfusion en interrompant de multiples niveaux de la cascade inflammatoire et, selon une nouvelle observation, les héparines inhibent l'activation du facteur de transcription proinflammatoire NF-λB.

3. 发明申请

WO9738699A2 USE OF ALKYLARYL POLYETHER ALCOHOL POLYMERS FOR THE TREATMENT OF CHRONIC PULMONARY INFLAMMATION 审中-公开
标题翻译：用于治疗慢性肺动脉炎的烷基聚醚醇聚合物的应用
公开(公告)号：WO9738699A2
公开(公告)日：1997-10-23
申请号：PCT/US9706150
申请日：1997-04-14
申请人： CHARLOTTE MECKLENBURG HOSPITAL , GHIO ANDREW J , KENNEDY THOMAS P
发明人： GHIO ANDREW J , KENNEDY THOMAS P
IPC分类号： A61K9/06 , A61K9/10 , A61K9/12 , A61K31/573 , A61K31/765 , A61K31/77 , A61K31/775 , A61P17/00 , A61P29/00 , A61P43/00
CPC分类号： A61K31/765 , A61K31/77 , A61K31/775 , Y10S514/828 , Y10S514/851 , Y10S514/887 , A61K2300/00
摘要： A method and medicant for the inhibition of activation of the nuclear transcription NF- kappa B comprising administering an effective amount of a compound of formula (I) where R = ethylene, R´= C4 to C14 straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably, the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition, a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, is provided.
摘要翻译：一种用于抑制核转录NF-κB活化的方法和药物，包括给予有效量的式（I）化合物，其中R =亚乙基，R'= C 4至C 14直链或支链烷基，x较大大于1，y = 8〜18。药物优选通过雾化进入哺乳动物呼吸系统。该药物也可以应用于哺乳动物皮肤。优选地，该药物包括生理上可接受的载体，其可以选自缓冲盐水，等渗盐水，生理盐水，石油基软膏和U.S.P。冷奶油还提供了一种方法，其中所述药物包括抗炎类固醇。此外，提供了治疗皮肤炎症性疾病，抑制促炎细胞因子TNF，IL-1，IL-6，IL-8和生长因子GM-CSF的分泌的方法和药物。

4. 发明申请

WO0182918A9 METHOD FOR THE PREVENTION OF APOPTOSIS 审中-公开
标题翻译：预防细胞凋亡的方法
公开(公告)号：WO0182918A9
公开(公告)日：2002-08-08
申请号：PCT/US0140639
申请日：2001-04-30
申请人： CHARLOTTE MECKLENBURG HOSPITAL , KENNEDY THOMAS P
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/04 , A61P9/10 , A61P43/00 , C08B37/10
CPC分类号： A61K31/727
摘要： et effet a été attribué à l'inhibition du complément, mais l'héparine présente également d'autres activités pouvant diminuer l'ischémie-reperfusion. Afin d'analyser ces mécanismes plus avant, nous avons comparé l'héparine et une héparine non anticoagulante O-désulfatée à activité anti-complément largement réduite. Administrée lors de la reperfusion de l'artère coronaire dans un modèle canin d'infarctus du myocarde, à la fois l'héparine et l'héparine O-désulfatée réduisent de manière égale l'adhérence de neutrophiles à l'endothélium de l'artère coronaire ischémiée et reperfusée, l'afflux de neutrophiles dans le myocarde ischémié et reperfusé, la nécrose myocardique et la libération de créatine kinase dans le plasma. L'héparine et l'héparine O-désulfatée empêchent également un dysfonctionnement de la relaxation coronaire dépendant de l'endothélium à la suite d'une lésion ischémique. En outre, l'héparine et l'héparine O-désulfatée inhibent la translocation du factllules endothéliales humaines et réduisent la liaison ADN NF-λB dans l'endothélium humain et le myocarde de rat ischémié et reperfusé. Ainsi, l'héparine et l'héparine non anticoagulante diminuent la lésion d'ischémie-reperfusion en interrompant de multiples niveaux de la cascade inflammatoire et, selon une nouvelle observation, les héparines inhibent l'activation du facteur de transcription proinflammatoire NF-λB.
摘要翻译：并且效果被归因于补体抑制，但肝素还具有可以减少缺血再灌注的其他活性。为了进一步分析这些机制，我们将肝素与O-脱硫酸非抗凝血肝素进行了比较，大大降低了抗补体活性。在心肌梗死的狗模型冠状动脉的再灌注期间施用时，既肝素和O-脱硫酸化肝素同样减少到动脉的内皮嗜中性粒细胞的粘附冠状动脉缺血和reperfusée，在局部缺血和再灌注的心肌，心肌坏死和血浆肌酸激酶的嗜中性粒细胞释放的涌入。肝素和O-脱硫酸肝素也可预防缺血性损伤后内皮依赖性冠脉舒张功能障碍。此外，肝素和O-脱硫酸化肝素抑制人内皮factllules的易位和减少在人内皮细胞和心肌缺血和再灌注大鼠结合DNA的NF-κB。因此，肝素和非抗凝血肝素降低了缺血再灌注损伤，中断炎症级联的多个级别，并且根据一个新的观察，肝素抑制促炎转录因子的NF-κB的活化。

5. 发明公开

EP1282411A4 METHOD OF TREATING CANCER 审中-公开
标题翻译：方法治疗癌症的
公开(公告)号：EP1282411A4
公开(公告)日：2008-05-21
申请号：EP01927380
申请日：2001-03-02
申请人： CHARLOTTE MECKLENBURG HOSPITAL
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/05 , A61K31/122 , A61K31/198 , A61K31/221 , A61K31/28 , A61K31/366 , A61K31/37 , A61K31/41 , A61K31/44 , A61K31/452 , A61K31/66 , A61K38/44 , A61K45/06 , A61P35/00
CPC分类号： A61K45/06 , A61K31/05 , A61K31/122 , A61K31/198 , A61K31/221 , A61K31/28 , A61K31/366 , A61K31/37 , A61K31/41 , A61K31/452 , A61K31/66 , A61K38/44 , C12Y111/01006 , C12Y111/01009 , A61K2300/00

6. 发明专利

AT285782T 未知
公开(公告)号：AT285782T
公开(公告)日：2005-01-15
申请号：AT97922426
申请日：1997-04-23
申请人： CHARLOTTE MECKLENBURG HOSPITAL
发明人： KENNEDY THOMAS P
IPC分类号： A61K47/32 , A61K9/12 , A61K31/56 , A61K31/573 , A61K31/765 , A61P11/02 , A61P11/04 , A61P11/06 , A61K31/77

7. 发明专利

CA2251384A1 USE OF ALKYLARYL POLYETHER ALCOHOL POLYMERS FOR THE INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-XB 未知
公开(公告)号：CA2251384A1
公开(公告)日：1997-10-23
申请号：CA2251384
申请日：1997-04-14
申请人： CHARLOTTE MECKLENBURG HOSPITAL
发明人： KENNEDY THOMAS P , GHIO ANDREW J
IPC分类号： A61K9/06 , A61K9/10 , A61K9/12 , A61K31/573 , A61K31/765 , A61K31/77 , A61K31/775 , A61P17/00 , A61P29/00 , A61P43/00 , A61K31/56
摘要： A method and medicant for the inhibition of activation of the nuclear transcription NF-B comprising administering an effective amount of a compound of formula (I) where R = ethylene, R~= C4 to C14 straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably, the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition, a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, is provided.

8. 发明专利

AU5981101A Method for the prevention of apoptosis 未知
公开(公告)号：AU5981101A
公开(公告)日：2001-11-12
申请号：AU5981101
申请日：2001-04-30
申请人： CHARLOTTE MECKLENBURG HOSPITAL
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/04 , A61P9/10 , A61P43/00 , C08B37/10 , A61K31/00
摘要： Heparin reduces ischemia-reperfusion injury to myocardium. This effect has been attributed complement inhibition, but heparin also has other activities that might diminish ischemia-reperfusion. To further probe these mechanisms, we compared heparin and an O-desulfated nonanticoagulant heparin with greatly reduced anti-complement activity. Given at the time of coronary artery reperfusion in a canine model of myocardial infarction, both heparin and O-desulfated heparin equally reduced neutrophil adherence to ischemic-reperfused coronary artery endothelium, influx of neutrophils into ischemic-reperfused myocardium, myocardial necrosis and release of creatine kinase into plasma. Heparin and O-desulfated heparin also prevented dysfunction of endothelial-dependent coronary relaxation following ischemic injury. In addition, heparin and O-desulfated heparin inhibited translocation of the transcription factor NF-kappaB from cytoplasm to the nucleus in human endothelial cells and decreased NF-kappaB DNA binding in human endothelium and ischemic-reperfused rat myocardium. Thus, heparin and nonanticoagulant heparin decrease ischemia-reperfusion injury by disrupting multiple levels of the inflammatory cascade, including the novel observation that heparins inhibit activation of the pro-inflammatory transcription factor NF-kappaB.

9. 发明专利

AU7370100A Method of inhibiting nf-kappab with heparin 未知
公开(公告)号：AU7370100A
公开(公告)日：2001-04-17
申请号：AU7370100
申请日：2000-09-12
申请人： CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/00 , A61P29/00 , A61K31/7024

10. 发明专利

CA2407806C USE OF HEPARIN OR NONANTICOAGULANT HEPARIN FOR INHIBITING APOPTOSIS ARISING FROM ISCHEMIA PERFUSION INJURY 未知
公开(公告)号：CA2407806C
公开(公告)日：2012-04-17
申请号：CA2407806
申请日：2001-04-30
申请人： CHARLOTTE MECKLENBURG HOSPITAL
发明人： KENNEDY THOMAS P
IPC分类号： A61K31/727 , A61P9/04 , A61P9/10 , A61P43/00 , C08B37/10
摘要： Heparin reduces ischemia-reperfusion injury to myocardium. This effect has been attributed complement inhibition, but heparin also has other activities that might diminish ischemia-reperfusion. To further probe these mechanisms, we compared heparin and an O-desulfated nonanticoagulant heparin with greatly reduced anti-complement activity. Given at the time of coronary artery reperfusion in a canine model of myocardial infarction, both heparin and O-desulfated heparin equally reduced neutrophil adherence to ischemic-reperfused coronary artery endothelium, influx of neutrophils into ischemic-reperfused myocardium, myocardial necrosis and release of creatine kinase into plasma. Heparin and O-desulfated heparin also prevented dysfunction of endothelial-dependent coronary relaxation following ischemic injury. In addition, heparin and O-desulfated heparin inhibited translocation of the transcription factor NF-.KAPPA.B from cytoplasm to the nucleus in human endothelial cells and decreased NF-.KAPPA.B DNA binding in human endothelium and ischemic-reperfused rat myocardium. Thus, heparin and nonanticoagulant heparin decrease ischemia-reperfusion injury by disrupting multiple levels of the inflammatory cascade, including the novel observation that heparins inhibit activation of the pro-inflammatory transcription factor NF-.KAPPA.B.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式